The UK-based consumer healthcare company will be modernizing its facility along Brook Road, where it conducts R&D for such ...
The global antacids market is on track for substantial expansion, with projections indicating a rise from USD 6,971.2 million ...
Based in the United Kingdom, Haleon makes consumer health care products, including Advil, Centrum Multivitamin and Aquafresh ...
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
Haleon was formed in 2019 by merging the Pfizer’s and GSK’s consumer healthcare business. After the recent sale, Pfizer’s stake in Haleon will be reduced to 7.3%. This will boost Pfizer’s ...
Once complete, Pfizer's stake in Haleon will fall from 15.0% to around 7.3%. Pfizer's move comes after Haleon's spin-off as an independent consumer healthcare company, part of plans to reshape its ...
The sale represents nearly 7.7% of Haleon's issued share capital. Haleon was formed in 2019 through a merger of the consumer healthcare businesses of GlaxoSmithKline (GSK) and Pfizer. Haleon was ...
A dip in inflation today eased pressure on Rachel Reeves and boosted hopes of a February interest rate cut. On the corporate front, Currys has raising profits guidance alongside a strong festive ...
JP Morgan Cazenove and Morgan Stanley were global coordinators on the sale of a 7.7% stake in the UK consumer healthcare ...
Pfizer Inc. (NYSE:PFE) has announced the sale of shares worth £2.50 billion ($3.05 billion) in British consumer healthcare giant Haleon, reducing its ownership stake to 7.3% from 15%. The transaction ...
According to J.P. Morgan, Pfizer is expected to sell approximately 700 million ordinary shares, thus lowering its stake from 15% to 7.3%, following Haleon's creation through a merger with GSK in 2019.
Pfizer sold shares of Haleon last year, including a £2.4 billion overnight sale in the autumn. Haleon was formed in 2022 from a combination of GSK Plc and Pfizer’s consumer-health units. The company ...